The life sciences start-up SEED Biosciences has finalised the series A raising CHF 1 million. The capital will support the company’s growth ambitions, product industrialisation, and will enable it to further develop its proprietary technology.
SEED Biosciences aims to set new standards in single-cell biology to accelerate the translation of precision medicine from research to personalised therapies to the benefit of patients. Its first product, DispenCell, enables scientists to isolate single cell lines 3x faster and 10x cheaper than existing solutions.
“Since launching our first product on the market in April this year, we have helped many scientists in Pharma companies and top-notch research centres to increase their productivity. Using DispenCell, our clients have solved important bottlenecks in workflows such as in single-cell cloning, CRISPR gene-editing and single-cell omics. This is undoubtedly due to the strength of DispenCell’s technology and data, which guarantee the traceability of the single-cell isolation process as well as the preservation of the most precious cells”, said Georges Muller, SEED Biosciences’ CEO and co-founder.
The start-up has achieved another achieved yet another milestone with the closing of its CHF 1 million series A round. The funding round was led by a new tech-savvy investor together with existing business angels from the biotech and lab automation industries. Proceeds from the round will enable SEED Biosciences to scale to meet strong demand in the single-cell biology field, putting the company on track to reach profitability in 2022.
“Our purpose is to help scientists around the world develop safer and more efficient biotherapies faster and at lower costs. With this funding, we are doubling our team to invest more resources into sales and manufacturing,” said Georges Muller, SEED Biosciences’ CEO and co-founder.
New chairman of the BoardChris Radloff has become Seed Biosciences’ new Chairman of the Board of Directors. He is a senior executive with a successful track record of leading global businesses in the laboratory equipment industry creating value and generating profitable growth. Throughout his career, he collected experience as General Manager/CEO in mid-size private organisations as well as in global public Fortune 500 companies. Currently acting as a board member in several start-ups, Chris brings to SEED Biosciences its accumulated expertise in developing international markets and driving innovation organically and through partnerships and acquisitions.
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines